New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 20, 2019 - The FDA announced the approval of Alnylam’s Givlaari (givosiran), for the treatment of adults with acute hepatic porphyria (AHP).
Download PDF
Return to publications
